From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
- PMID: 35720368
- PMCID: PMC9203678
- DOI: 10.3389/fimmu.2022.913215
From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
Abstract
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent cytotoxic mechanism that is mainly mediated in humans by natural killer (NK) cells. ADCC mediates the clinical benefit of several widely used cytolytic monoclonal antibodies (mAbs), and increasing its efficacy would improve cancer immunotherapy. CD16a is a receptor for the Fc portion of IgGs and is responsible to trigger NK cell-mediated ADCC. The knowledge of the mechanism of action of CD16a gave rise to several strategies to improve ADCC, by working on either the mAbs or the NK cell. In this review, we give an overview of CD16a biology and describe the latest strategies employed to improve antibody-dependent NK cell cytotoxicity.
Keywords: ADCC; CD16a; NK cells; cell therapy; monoclonal antibodies.
Copyright © 2022 Coënon and Villalba.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.Blood. 2020 Feb 6;135(6):399-410. doi: 10.1182/blood.2019000621. Blood. 2020. PMID: 31856277 Free PMC article.
-
Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.Front Immunol. 2018 Dec 6;9:2873. doi: 10.3389/fimmu.2018.02873. eCollection 2018. Front Immunol. 2018. PMID: 30574146 Free PMC article.
-
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.MAbs. 2024 Jan-Dec;16(1):2381261. doi: 10.1080/19420862.2024.2381261. Epub 2024 Jul 24. MAbs. 2024. PMID: 39048914 Free PMC article.
-
Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.J Leukoc Biol. 2019 Jun;105(6):1297-1303. doi: 10.1002/JLB.2MR1218-501R. Epub 2019 Feb 20. J Leukoc Biol. 2019. PMID: 30786043 Free PMC article. Review.
-
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells.Cancers (Basel). 2021 Jan 16;13(2):312. doi: 10.3390/cancers13020312. Cancers (Basel). 2021. PMID: 33467027 Free PMC article. Review.
Cited by
-
Identification of a novel ADCC-related gene signature for predicting the prognosis and therapy response in lung adenocarcinoma.Inflamm Res. 2024 May;73(5):841-866. doi: 10.1007/s00011-024-01871-y. Epub 2024 Mar 20. Inflamm Res. 2024. PMID: 38507067
-
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.J Hematol Oncol. 2023 Jul 27;16(1):83. doi: 10.1186/s13045-023-01482-w. J Hematol Oncol. 2023. PMID: 37501154 Free PMC article. Review.
-
Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms.Front Immunol. 2024 Dec 17;15:1520103. doi: 10.3389/fimmu.2024.1520103. eCollection 2024. Front Immunol. 2024. PMID: 39742266 Free PMC article.
-
Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46.Immune Netw. 2024 Aug 19;24(5):e34. doi: 10.4110/in.2024.24.e34. eCollection 2024 Oct. Immune Netw. 2024. PMID: 39513028 Free PMC article. Review.
-
Systems Biology-Driven Discovery of Host-Targeted Therapeutics for Oropouche Virus: Integrating Network Pharmacology, Molecular Docking, and Drug Repurposing.Pharmaceuticals (Basel). 2025 Apr 23;18(5):613. doi: 10.3390/ph18050613. Pharmaceuticals (Basel). 2025. PMID: 40430433 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources